![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA Gives Roche’s Tecentriq-Chemo Combo Priority Review
FDA Gives Roche’s Tecentriq-Chemo Combo Priority Review
![roche.gif](https://www.fdanews.com/ext/resources/test/Device_Images/roche.gif?t=1600727553&width=430)
The FDA granted priority review for Roche’s extensive-stage small cell lung cancer (ES-SCLC) treatment Tecentriq in combination with chemotherapy.
The treatment is intended for first-line treatment of patients with ES-SCLC, and the agency is expected to make a decision on Tecentriq’s approval by March 18, 2019.
Tecentriq has been approved by the FDA to treat patients suffering from metastatic non-small cell lung cancer who have seen the disease progress during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has ALK or EGFR abnormalities.
Upcoming Events
-
21Oct